Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D mutated metastatic colorectal cancer (mCRC)? A meta-analysis of 54 cases.
Authors:
- Volker HeinemannVHVolker Heinemann
- Anke Reinacher-SchickARAnke Reinacher-Schick
- Sebastian StintzingSSSebastian Stintzing
- Clemens Albrecht GiessenCGClemens Albrecht Giessen
- Andrea TannapfelATAndrea Tannapfel
- Ruediger P. LaubenderRLRuediger P. Laubender
- Thomas BrodowiczTBThomas Brodowicz
- Regina KnittelfelderRKRegina Knittelfelder
- Damir VrbanecDVDamir Vrbanec
- Wolff SchmiegelWSWolff Schmiegel
- Dominik Paul ModestDMDominik Paul Modest
- Christoph ZielinskiCZChristoph Zielinski
- 1 February 2012
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (4) , 511